Sygnature Discovery Limited

Activities: Research & Development

Trending Articles

  1. Wacker Biotech to manufacture protein ingredients for MinervaX's late-stage GBS vaccine The vaccine is currently being prepared for Phase III trials, and aims to protect mothers and their babies from group B streptococcus infections
  2. Novartis' Kisqali plus ET bags FDA approval for HR+/HER2- breast cancer The decision comes off the back of the Phase III NATALEE clinical trial, which diminished the risk of disease recurrence by 25.1%
  3. AstraZeneca opens a 'people hub' at its Macclesfield site The energy-efficient building will offer AZ employees a collaborative space
  4. Ensuring cGMP compliance in cell and gene therapy manufacturing 3P discusses how companies can scale up their CGT manufacturing protocols while remaining compliant with stringent global regulations
  5. Piramal Pharma's sustainability goals get SBTi-validated The company wants to reduce its scope 1 and 2 GHG emissions by 42% by 2030, and is also working on developing a carbon reduction plan

Upcoming event

Boston Biotech Week

23-26 September, 2024 | Convention and exhibition | Boston, US See all

Related Content

Finance

Sygnature Discovery invests £3.75m in compound management to provide cutting-edge hit finding capabilities

Sygnature Discovery has unveiled its latest investment in a state-of-the-art Azenta compound management storage system, which also provides the opportunity to store customer libraries
Drug Delivery

Sygnature acquires CRO NuChem Sciences

This acquisition cements Sygnature as one of the world’s largest players in integrated drug discovery phase solutions
Manufacturing

Sygnature launches in vivo model to profile early-stage anti-inflammatory drugs

The LPS in vivo model supports early-stage anti-inflammatory drug discovery in neuroinflammation, kidney, and systemic inflammation
Research & Development

Accelerating drug discovery with market leading cell line generation

In January 2023, integrated drug discovery company Sygnature Discovery announced the acquisition of SB Drug Discovery, a world-leading provider of ion channel and receptor drug discovery research delivering cell line generation and compound screening solutions in neuroscience and other therapeutic indications
Finance

Sygnature Discovery acquires Peak Proteins

Peak Proteins’ core technologies include protein expression and purification
Research & Development

Sygnature Discovery appoints Chair

As Chairman, Dr Woler will support Sygnature Discovery’s recruitment efforts, broaden its therapeutic areas and grow its presence in North America
Finance

Sygnature Discovery appoints Chief Financial Officer

"This is a fantastic place to work and home to real scientific innovation, so there are plenty of brilliant opportunities ahead of us."
Subscribe now